Neuronetics Inc

Neuronetics narrowed its full-year 2026 total revenue guidance to a range of $160 million to $164 million, compared with prior guidance of $160 million to $166 million. The company also raised its gross margin forecast to between 48% and 50%, up from 47% to 49%, and lowered operating expense guidance to $95 million to $100 million from $100 million to $105 million. Second-quarter total revenue rose 9.1% to $41.6 million, with Greenbrook revenue up 16.8% to $26.9 million while NeuroStar revenue dipped 2.7% to $14.7 million. Management highlighted a strategic shift toward broader NeuroStar ownership models, including outright purchase and lease-financed options, which may cause second-half revenue to be choppier but positions the company for sustainable growth in 2027. The company reported a net loss of $3.4 million, or $0.05 per share, and positive adjusted EBITDA of $0.3 million, with total cash of $25 million as of June 30.

Neuronetics announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. The nearly 7,000-square-foot facility is the largest Greenbrook center to date and will serve as a national blueprint for advanced, patient-centered mental health care delivery. Overseen by Neuronetics’ Chief Medical Officer Geoffrey Grammer, M.D., the center is designed to support high-volume NeuroStar TMS and SPRAVATO operations and is REMS-certified. It will also function as Greenbrook’s National Center for Clinical Innovation and Research, piloting emerging treatment modalities before broader network implementation. The Rockville location offers NeuroStar Advanced Therapy for major depressive disorder and obsessive-compulsive disorder, as well as SPRAVATO nasal spray for treatment-resistant depression.

Neuronetics has appointed Nir Naor as Chief Financial Officer effective July 23, 2026, and promoted Cory Anderson to Executive Vice President and General Manager of Greenbrook effective July 1, 2026. Naor brings more than 20 years of finance and life sciences experience, most recently serving as CFO of Axogen, and previously as CFO of Arbor Pharmaceuticals and the U.S./Americas business of Mölnlycke. Anderson has been with Neuronetics for over five years, most recently as Senior Vice President and Chief Technology Officer. The company also announced that Executive VP, Chief Legal Officer and Corporate Secretary Andrew Macan will step down effective August 15, 2026. Neuronetics shares closed Monday at $2.02, up 24.69%, before dipping 1.49% to $1.99 in after-hours trading.